CA Patent

CA2517572C — Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia

Assigned to Merck Sharp and Dohme LLC · Expires 2011-12-13 · 14y expired

What this patent protects

The present invention provides substituted azetidinone compounds of formula (I), formulations and processes for preparing the same which can be useful for treating vascular conditions such as atherosclerosis or hypercholesterolemia, diabetes, obesity, stroke, demyelination and lo…

USPTO Abstract

The present invention provides substituted azetidinone compounds of formula (I), formulations and processes for preparing the same which can be useful for treating vascular conditions such as atherosclerosis or hypercholesterolemia, diabetes, obesity, stroke, demyelination and lowering plasma levels of sterols and/or stanols in a subject.

Drugs covered by this patent

Patent Metadata

Patent number
CA2517572C
Jurisdiction
CA
Classification
Expires
2011-12-13
Drug substance claim
No
Drug product claim
No
Assignee
Merck Sharp and Dohme LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.